JPS5850739B2 - Garlic tablets for moxibustion treatment - Google Patents
Garlic tablets for moxibustion treatmentInfo
- Publication number
- JPS5850739B2 JPS5850739B2 JP11611780A JP11611780A JPS5850739B2 JP S5850739 B2 JPS5850739 B2 JP S5850739B2 JP 11611780 A JP11611780 A JP 11611780A JP 11611780 A JP11611780 A JP 11611780A JP S5850739 B2 JPS5850739 B2 JP S5850739B2
- Authority
- JP
- Japan
- Prior art keywords
- powder
- garlic
- moxibustion
- tablet
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 240000002234 Allium sativum Species 0.000 title claims description 26
- 235000004611 garlic Nutrition 0.000 title claims description 26
- 239000000843 powder Substances 0.000 claims description 51
- 229940029982 garlic powder Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000155 melt Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 241000411851 herbal medicine Species 0.000 description 8
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 244000223014 Syzygium aromaticum Species 0.000 description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Description
【発明の詳細な説明】 本発明は灸治療用ニンニク錠剤に関するものである。[Detailed description of the invention] The present invention relates to garlic tablets for moxibustion treatment.
その目的は、もぐさによる灸治療にニンニクを併用する
謂ゆる「ニンニク灸」が、手軽にかつ有効に達成できる
ニンニク錠剤を提供することにある。The purpose is to provide a garlic tablet that can easily and effectively achieve so-called "garlic moxibustion" in which moxibustion treatment using moxa is combined with garlic.
従来より灸治療は漢方による経のツボにもぐさを置いて
これに点火して行われ、色々な病気の治療や予防に利用
されているが、その効果を一層高めるためにニンニク、
味噌、漢方生薬などが併用される謂ゆる「ニンニク灸」
などが盛んに行われる様になって来た。Traditionally, moxibustion treatment has been performed by placing Chinese herbal grass on meridian acupuncture points and igniting it, and it has been used to treat and prevent various diseases, but to further enhance the effect, moxibustion, such as garlic, etc.
So-called ``garlic moxibustion'' that uses miso, Chinese herbal medicine, etc.
It has become more common to do so.
しかし、これらニンニク等の生薬を使用するにあたって
、ニンニクの輪切りや摺りおろしたもの、また生薬類に
ニンニクも含む)の練ったもの、などを利用するためこ
の使用が大変わずられしく面倒であり、したがって謂ゆ
る「ニンニク灸」等は非常に不便なものとされていたの
である。However, when using these herbal medicines such as garlic, it is very cumbersome and troublesome to use garlic, which is sliced or grated, or kneaded with garlic (herbal medicines include garlic). Therefore, so-called ``garlic moxibustion'' was considered extremely inconvenient.
ところで、最近になって「ロケット灸」と称されるもぐ
さの加工製品が市販される様になった。By the way, recently, processed moxa products called "rocket moxibustion" have become commercially available.
この「ロケット灸」は後で図面で説明する様に、中央に
透穴を有する台座の上にもぐさを薄紙で巻いた小さな棒
状もぐさを立設したもので、この台座の下拵に粘着剤が
塗布してあって皮膚に付着させるという無痕点灸製品で
ある。As explained in the drawings later, this "rocket moxibustion" consists of a small stick-shaped moxa wrapped in tissue paper on a pedestal with a through hole in the center, and an adhesive is attached to the bottom of the pedestal. It is a markless moxibustion product that is applied and attached to the skin.
本発明者はこの謂ゆる「ロケット灸」の台座の下面部に
錠剤が挿入できる嵌合穴を設けてここへニンニク錠剤を
嵌め込んでもぐさに点火したならばニンニク灸が手軽に
達成できると考え、その様なニンニク錠剤を得るべく鋭
意検討を重ねた結果本発明に達したのである。The inventor of the present invention believes that garlic moxibustion can be easily achieved by providing a fitting hole into which a tablet can be inserted into the bottom of the base of the so-called "rocket moxibustion", fitting a garlic tablet into the hole, and igniting the clove. As a result of extensive research in order to obtain such garlic tablets, we have arrived at the present invention.
すなわち、ニンニク粉末、比較的低温で熔融する熔融性
粉末、及び形状保持用粉末を、必須成分として含有する
粉末混合物を錠剤機にて製錠したことを特徴とする灸治
療用ニンニク錠剤を発明するに至ったのである。That is, to invent a garlic tablet for moxibustion treatment, which is made by tableting a powder mixture containing garlic powder, a meltable powder that melts at a relatively low temperature, and a shape-retaining powder as essential components using a tablet machine. It has come to this.
つまり本発明は、ニンニク粉末、熔融性粉末、及び形状
保持用粉末を必杉成分として含み、その他必要に応じて
他の漢方生薬の粉末や滑沢剤粉末などを配合した混合粉
末を錠剤に底形したものである。In other words, the present invention provides tablets with a mixed powder containing garlic powder, melting powder, and shape-retaining powder as essential ingredients, and other Chinese herbal medicine powders, lubricant powders, etc. as necessary. It is shaped.
本発明におけるニンニク粉末は「ガーリックパウダー」
として市販されているものが利用でき、ニンニクを粉末
状に加工したものである。Garlic powder in the present invention is "garlic powder"
Garlic can be used commercially as a powdered garlic powder.
また、本発明における熔融性粉末とは謂ゆる軟膏基剤や
座薬基剤として利用されるもので、比較的低温で熔融す
る粉末である。Further, the meltable powder in the present invention is used as a so-called ointment base or suppository base, and is a powder that melts at a relatively low temperature.
例えば、ミツロウ、木ロウ、カンデリラロウなどのワッ
クス類、ステアリルアルコール、セタノールなどの高級
アルコール、ステアリン酸、パルミチン酸などの高級脂
肪酸、ラウリン酸からステアリン酸までの飽和脂脂肪モ
ノ・シイ・トリグリセリドなどの高級脂肪酸エステル類
、及びポリエチレングリコールなとその他各種の粉末が
あげられ、これらを単独で用いてもよいし、適宜併用し
て使用してもよいものである。For example, waxes such as beeswax, wood wax, and candelilla wax, higher alcohols such as stearyl alcohol and cetanol, higher fatty acids such as stearic acid and palmitic acid, and saturated fats from lauric acid to stearic acid. Examples include fatty acid esters, polyethylene glycol, and various other powders, which may be used alone or in appropriate combinations.
この熔融性粉末は灸治療時のもぐさの点火によりこの加
熱で熔融してニンニクやその他の生薬中の薬効成分を抽
出し油状の形で皮膚へ付着し有効成分が体内に吸収しや
すい様に作用するもので、ニンニク錠剤の皮膚への接着
と成分吸収を促進するという効果を有するものである。This meltable powder is melted by heating when the moxa is ignited during moxibustion treatment, extracts the medicinal ingredients from garlic and other herbal medicines, and adheres to the skin in an oily form, making it easier for the active ingredients to be absorbed into the body. It has the effect of promoting adhesion of garlic tablets to the skin and absorption of ingredients.
本発明の最大の特徴はこの熔融性粉末を錠剤に混入する
という従来全く利用されていなかった処方を用いたこと
である。The greatest feature of the present invention is that it uses a formulation that has never been used in the past, in which this meltable powder is mixed into tablets.
つまり通常の座薬などは基剤を熔融混合したのち型に流
し込んで冷却固化させる方法であり、本発明とは全く異
なる製法である。In other words, ordinary suppositories are manufactured by melting and mixing base materials, pouring into molds, and cooling and solidifying, which is a completely different manufacturing method from the present invention.
また、この熔融性粉末を用いないで単に通常錠剤の製法
によりニンニク粉末を製錠した場合は僅かに含まれる水
分が薬効成分の伝達の役目を行なうがその効果はきわめ
て低いものである。Furthermore, when garlic powder is tabletted simply by a conventional tablet manufacturing method without using this meltable powder, the small amount of water contained plays a role in transmitting the medicinal ingredients, but its effectiveness is extremely low.
なお、この場合使用前に水で湿潤させてから使用する方
法も考えられるが非常に面倒である。In this case, it may be possible to wet the material with water before use, but this is very troublesome.
この熔融性粉末は比較的低温(約40〜70℃)で熔融
しかつ皮膚刺激性の少いワックス状のものを使用するこ
とが望ましいもので、軟膏や座薬の基剤として使用され
る成分で油脂をよく溶かし水によって乳濁液を生ずる様
な熔融性粉末を使用すると、皮膚から出る水分と相乗的
に効果を促進し有効成分の皮膚への吸収が一段とすぐれ
たものになるのである。It is desirable to use a wax-like meltable powder that melts at a relatively low temperature (approximately 40 to 70°C) and is less irritating to the skin, and is an ingredient used as a base for ointments and suppositories. By using a meltable powder that dissolves fats and oils well and forms an emulsion with water, the effect is synergistically promoted with the moisture released from the skin, resulting in even better absorption of the active ingredients into the skin.
さらにこの熔融性粉末によって灸の熱さが皮膚へ伝わる
温度も適度なものに加減されるし、この油成分は万一の
火傷のときの薬効も有するものである。Furthermore, this meltable powder moderates the temperature at which the heat of moxibustion is transmitted to the skin, and the oil component also has medicinal properties in the event of a burn.
この熔融性粉末の配合量は製品錠剤中に20〜60%の
割合で含有されることが好ましく、20%未満ではもぐ
さに点火してもやや湿った状態になるだけでニンニク成
分の抽出や皮膚への吸収促進作用が低下し、また皮膚へ
の接着力も劣る様になり、一方この配合量が60%をこ
えると主成分であるニンニク粉末やその他の生薬粉末等
の割合が減少して有効が著るしく低下するのである。It is preferable that the blended amount of this meltable powder is 20 to 60% in the product tablet.If it is less than 20%, even if the moxa is ignited, it will only be in a slightly damp state, and the garlic components will not be extracted or the skin will be exposed. On the other hand, if this amount exceeds 60%, the proportion of the main ingredients such as garlic powder and other herbal medicine powders decreases, making it less effective. This results in a significant decline.
次に本発明に使用される形状保持用粉末とは前記の熔融
性粉末が一時に熔融して熱い油状物が急激に皮膚に付着
するのを防ぐために添加されるもので、熔融性粉末の熔
融時にも錠剤の形状を保持する効果を有するものである
。Next, the shape-retaining powder used in the present invention is added to prevent the above-mentioned meltable powder from melting all at once and causing hot oily substances to suddenly adhere to the skin. It also has the effect of retaining the shape of the tablet.
この形状保持用粉末は、例えばタルク、カオリン、炭酸
カルシウム、軽質無水ケイ酸、リン酸水素カルシウムな
ど通常の無機質粉末であれば何でも用いることができ、
その他融点の高い有機物の粉末、例えば結晶セルロース
なども使用できるものである。This shape-retaining powder can be any ordinary inorganic powder such as talc, kaolin, calcium carbonate, light anhydrous silicic acid, calcium hydrogen phosphate, etc.
Other powders of organic substances with high melting points, such as crystalline cellulose, can also be used.
この形状保持用粉末は前記の如くもぐさ点火時に錠剤が
熔融して皮膚に熱い油状物が急に付着するのを防止する
効果を有し、また灸終了後の錠剤の残物を除去しやすい
という効果や、製錠時の錠剤軟化を防止する効果も発揮
するものである。As mentioned above, this shape-retaining powder has the effect of preventing the tablet from melting and hot oily substances suddenly adhering to the skin when moxa is ignited, and is also said to make it easier to remove tablet residue after moxibustion. It also exhibits the effect of preventing tablet softening during tabletting.
この形状保持用粉末の配合量は製品錠剤中に10〜30
%の割合で含有されることが好ましく、10%未満では
形状保持効果が達成されないし、30%をこえると熔融
性粉末の熔融を妨げ薬効成分の抽出・吸収等の本発明錠
剤の本質的効果を損なうものとなるのである。The amount of this shape-retaining powder is 10 to 30% in the product tablet.
%. If the content is less than 10%, the shape retention effect will not be achieved, and if it exceeds 30%, the melting of the meltable powder will be inhibited and the essential effects of the tablet of the present invention, such as extraction and absorption of medicinal ingredients, will be reduced. This results in a loss of quality.
本発明錠剤において、ニンニク粉末の外に、他の漢方生
薬の粉末、例えばニラケイ、ショウキョウ、チョウジ、
モツコウ、ビヤクシ、ソウジュラ、モツヤク、ヨゴミ、
などの各種粉末を適宜併用して配合してやると色々な治
療効果が期待でき一層好ましいものとなる。In the tablet of the present invention, in addition to garlic powder, powders of other Chinese herbal medicines, such as nirakei, ginger, clove,
Motsukou, Byakushi, Sojura, Motsuyaku, Yogomi,
Various therapeutic effects can be expected and it is even more preferable to combine various powders such as these as appropriate.
このニンニク粉末、その他の生薬粉末などの生薬成分粉
末の配合量は製品錠剤中に50%以下であることが好ま
しく、50%をこえると錠剤成形が非常に困難となるの
である。It is preferable that the amount of garlic powder, other herbal medicine powders, and other herbal drug ingredient powders in the product tablet be 50% or less, and if it exceeds 50%, tablet forming becomes extremely difficult.
しかし薬効上これら主薬成分粉末は少くとも25%以上
含有されることが望ましいものである。However, from the viewpoint of medicinal efficacy, it is desirable that the powder contains at least 25% of these main drug ingredient powders.
また、本発明錠剤中に製造時の打錠性をよくするために
タルクやステアリン酸マグネシウムの如き滑沢剤粉末を
少量添加してやることが望ましいものである。It is also desirable to add a small amount of lubricant powder such as talc or magnesium stearate to the tablets of the present invention to improve tableting properties during manufacture.
本発明は以上の如き各種粉末を良く混合し錠剤機にて平
錠剤に製錠したものである。In the present invention, the various powders described above are thoroughly mixed and tableted into flat tablets using a tablet machine.
一般に座薬などの製法は融解法、クリーム融解法などで
行われ、これは特別の装置機器を必要とし製造に手間が
かかるが、本発明においては薬物・配合物・添加物等を
全部粉末とし、これらを混合して圧縮して打つ直打工程
で打錠するもので、工程上も非常にすぐれたものである
。Generally, suppositories are manufactured using the melting method, cream melting method, etc., which requires special equipment and takes time to manufacture. However, in the present invention, all drugs, compounds, additives, etc. are made into powder, It is made into tablets using a direct compression process in which these ingredients are mixed, compressed, and pressed, making it an extremely superior process.
また、普通錠剤を製造するときは圧縮熱が発生し熔融物
は軟化するので添加できないとされていたのであるが、
本発明においては前記の形状保持用粉末が入っているた
め熔融性粉末が軟化しても製錠しにくくなる様なことは
なく容易に打錠できるものである。Also, when manufacturing ordinary tablets, compression heat is generated and the melt becomes soft, so it was said that it could not be added.
In the present invention, since the above-mentioned shape-retaining powder is contained, even if the meltable powder softens, it does not become difficult to form tablets, and tablets can be easily formed.
但し、この製錠に際しては20℃以下の室温で行なうこ
とが望ましいもので、また製品錠剤の長期保存は30’
C以下の温度で行なうことが好ましいものである。However, it is preferable to make tablets at room temperature below 20°C, and long-term storage of product tablets is limited to 30'
It is preferable to conduct the reaction at a temperature of C or lower.
以上の様にして得られた本発明錠剤は下記の如くにして
使用するのである。The tablet of the present invention obtained as described above is used in the following manner.
図は本発明錠剤の使用法を示した拡大断面図である。The figure is an enlarged sectional view showing how to use the tablet of the present invention.
この図の様に無痕点灸として市販されている「ロケット
灸」は、台座1の中央に透穴2があってこの透穴2の上
に薄紙3で巻いたもぐさ4が立設されているもので、台
座1の下面には皮膚に付着させるための粘着剤5が塗布
されている。As shown in this figure, "Rocket moxibustion", which is commercially available as a markless point moxibustion, has a through hole 2 in the center of a pedestal 1, and a moxa 4 wrapped with thin paper 3 is placed upright above the through hole 2. An adhesive 5 is applied to the lower surface of the pedestal 1 for adhesion to the skin.
そして台座1の上面には消火を完結させるためのアルミ
フィルム6が貼着されている。An aluminum film 6 is attached to the top surface of the pedestal 1 to complete extinguishing the fire.
この台座1の大きさは直径約10〜17關位でもぐさ4
の直径は3〜6關で高さは5〜10mm位である。The size of this pedestal 1 is about 10 to 17 inches in diameter and 4 bushes.
The diameter is 3 to 6 mm and the height is about 5 to 10 mm.
この「ロケット灸」の台座1の下面に平錠剤が丁度入る
様な直径約5〜8皿で深さ1〜2田の嵌合穴7を設けて
、ここに本発明錠剤8を挿入し、そしてこの「ロケット
灸」と共に皮膚へ付着させて後、もぐさ4に点火するの
である。A fitting hole 7 with a diameter of about 5 to 8 plates and a depth of 1 to 2 mm is provided on the underside of the pedestal 1 of this "rocket moxibustion", and the tablet 8 of the present invention is inserted therein, so that a flat tablet can fit therein. Then, after attaching it to the skin along with this "rocket moxibustion", moxa 4 is ignited.
このもぐさ4の点火によって、本発明錠剤8は前記した
如く、形状保持用粉末の作用でこの錠剤の形状を保持し
つつ、熔融性粉末は熔融して薬効成分を抽出すると共に
皮膚への付着と有効成分の吸収を促進し、きわめてすぐ
れたニンニク灸効果が達成されるのである。By igniting the moxa 4, the tablet 8 of the present invention maintains its shape due to the action of the shape-retaining powder, while the meltable powder melts and extracts the medicinal ingredients and prevents it from adhering to the skin. This promotes absorption of the active ingredients and achieves excellent garlic moxibustion effects.
以上詳細に説明した様に、本発明は謂ゆる「ロケット灸
」と称される無痕点灸製品に使用できる灸治療用ニンニ
ク錠剤であり、このニンニク錠剤を「ロケット灸」の下
面に入れてもぐさに点火するだけという簡単な作業で手
軽にニンニク灸が達成されるもので、しかもこのニンニ
ク錠剤には薬効成分が有効に抽出・吸収され、かつあま
り熱くなり過ぎない様な配合物が混入されているため薬
効上も使用上もきわめてすぐれた効果を奏するものであ
る。As explained in detail above, the present invention is a garlic tablet for moxibustion treatment that can be used in a markless moxibustion product called "rocket moxibustion", and the garlic tablet is placed on the underside of the "rocket moxibustion". Garlic moxibustion can be achieved easily by simply lighting moxa, and the garlic tablets are mixed with a compound that effectively extracts and absorbs the medicinal ingredients and does not cause the tablets to become too hot. Because of this, it has excellent medicinal and usage effects.
実施例
下記の如き組成で配合した混合粉末を18°Cの温度で
錠剤機にて製錠した。Example A mixed powder having the composition shown below was tableted using a tablet machine at a temperature of 18°C.
打錠は伺らの支障もなく行われ、得られたニンニク錠剤
を謂ゆる「ロケット灸」の下面に入れてニンニク灸を行
なったところ、すぐれた灸治療効果が得られ、しかも取
扱いも簡単で熱さは適度であり非常に好ましいものであ
った。The tablets were compressed without any trouble, and when the resulting garlic tablets were placed under the so-called ``rocket moxibustion'' and garlic moxibustion was performed, excellent moxibustion therapeutic effects were obtained, and they were easy to handle. The heat was moderate and very pleasant.
配合組成 ニンニク粉末 14,6重量部 その他の生薬粉末 18.3重量部 熔融性粉末 41.6重量部 形状保持用粉末 23.2重量部 滑沢剤粉末 8.1重量部 (計) (105,8)但し、 その他の生薬粉末は下記の配合による。Mixture composition Garlic powder 14.6 parts by weight Other crude drug powder 18.3 parts by weight Meltable powder 41.6 parts by weight Shape-retaining powder 23.2 parts by weight Lubricant powder 8.1 parts by weight (Total) (105,8) However, Other crude drug powders are formulated as follows.
ニラケイ 2.2 重量部ショウキョウ
2.2 重量部チョウジ 2
.2 重量部モツコク 2.2 重量部
ビヤクシ 2.2 重量部ソウジュラ
2.2 重量部モツヤク 2
.2 重量部ヨゴミ 2.9 重量
部熔融性粉末は下記の配合による。Nirakei 2.2 parts by weight ginger 2.2 parts by weight clove 2
.. 2 parts by weight Motsukoku 2.2 parts by weight Byakushi 2.2 parts by weight Soudura
2.2 Weight part Motsuyaku 2
.. 2 parts by weight Dirt 2.9 parts by weight The meltable powder has the following composition.
(1)平均分子量約7000で融点が60〜638Cの
ポリエチレングリコール ・・・・・・ 5.2重量部
(2) C1□〜C18の飽和脂肪酸のグリセリンエ
ステルで平均分子量710で融点42〜44℃のもの
・・・・・・29.1重量部(
3) ステアリルアルコール(融点58°C)7.3
重量部
形状保持用粉末は下記の配合による。(1) Polyethylene glycol with an average molecular weight of about 7,000 and a melting point of 60-638C...5.2 parts by weight (2) Glycerin ester of saturated fatty acids of C1□-C18 with an average molecular weight of 710 and a melting point of 42-44℃ things of
...29.1 parts by weight (
3) Stearyl alcohol (melting point 58°C) 7.3
The shape-retaining powder (parts by weight) has the following formulation.
軽質無水ケイ酸 ・・・・・・ 5重量部リ
ン酸水素カルシウム ・・・・・・10゜9重量部結
晶セルロース ・・・・・・ 7.3重量部滑
沢剤粉末は下記の配合による。Light anhydrous silicic acid: 5 parts by weight Calcium hydrogen phosphate: 10°9 parts by weight Crystalline cellulose: 7.3 parts by weight The lubricant powder has the following composition. .
タルク ・・・・・・ 6.6重量部
ステアリン酸マグネシウム・・・・・・ 1.5重量部Talc: 6.6 parts by weight Magnesium stearate: 1.5 parts by weight
図は本発明錠剤の使用法を示した拡大断面図である。
1・・・・・・台座、2・・・・・・透穴、3・・・・
・・薄紙、4・・・・・・もぐさ、5・・・・・・粘着
剤、6・・・・・・アルミフィルム、7・・・・・・嵌
合穴、8・・・・・・本発明錠剤。The figure is an enlarged sectional view showing how to use the tablet of the present invention. 1...Pedestal, 2...Through hole, 3...
... Thin paper, 4 ... Moxa, 5 ... Adhesive, 6 ... Aluminum film, 7 ... Fitting hole, 8 ... -Tablet of the present invention.
Claims (1)
及び形状保持用粉末を、必須成分として含有する粉末混
合物を錠剤機にて製錠したことを特徴とする灸治療用ニ
ンニク錠剤。1 Garlic powder, a meltable powder that melts at a relatively low temperature,
A garlic tablet for moxibustion treatment, characterized in that a powder mixture containing a shape-retaining powder and a shape-retaining powder is tableted using a tablet machine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11611780A JPS5850739B2 (en) | 1980-08-22 | 1980-08-22 | Garlic tablets for moxibustion treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11611780A JPS5850739B2 (en) | 1980-08-22 | 1980-08-22 | Garlic tablets for moxibustion treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5739844A JPS5739844A (en) | 1982-03-05 |
| JPS5850739B2 true JPS5850739B2 (en) | 1983-11-12 |
Family
ID=14679106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11611780A Expired JPS5850739B2 (en) | 1980-08-22 | 1980-08-22 | Garlic tablets for moxibustion treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5850739B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003128536A (en) * | 2001-10-25 | 2003-05-08 | Kenji Sugibayashi | Percutaneous absorption preparation used in combination with warm heat treatment |
| JP4864172B2 (en) * | 2009-12-15 | 2012-02-01 | 三菱日立製鉄機械株式会社 | Cold rolled material manufacturing equipment and cold rolling method |
-
1980
- 1980-08-22 JP JP11611780A patent/JPS5850739B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5739844A (en) | 1982-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60128168T2 (en) | Tablet and method of making the same | |
| US4892890A (en) | External analgesic compositions | |
| DE60213190T2 (en) | TABLETS QUICKLY CRUMPING IN THE MOUTHHOUSE AND PROCESS FOR THEIR PRODUCTION | |
| US4786495A (en) | Therapeutic agents | |
| JP2002502806A (en) | Composition for treating bad breath | |
| GB1030127A (en) | Improvements in or relating to method of preparing sustained release pharmaceutical pellets and product thereof | |
| PL189358B1 (en) | Pharmaceutic composition for oral administration | |
| CN101919822B (en) | Tablet with improved combination properties and preparation method thereof | |
| US5916918A (en) | Method for treating a skin injury comprising topically applying acetylsalicylic acid | |
| US3515781A (en) | Cold capsule | |
| US3935310A (en) | Remedy for treatment of hemorrhoids | |
| CA1181345A (en) | Method for the preparation of pharmaceutical compositions for the treatment of skin | |
| JP2005082594A (en) | Pharmacological composition concealing bitterness | |
| US10342756B2 (en) | Hydrating lip balm composition | |
| JPS5850739B2 (en) | Garlic tablets for moxibustion treatment | |
| PL190733B1 (en) | Pharmaceutic preparations for treating henicrania, containing ibuprofen and domperidone | |
| IE33480B1 (en) | Pharmaceutical preparation | |
| RU2040252C1 (en) | Agent for healing wounds | |
| US2895881A (en) | Quinidine gluconate sustained medication tablet | |
| CN110548085A (en) | Medicine for treating burn and preparation method thereof | |
| CN100370974C (en) | Cancer treating | |
| CN112188886A (en) | Formulations for mask coating | |
| JPS5843365B2 (en) | Hydrophilic poultice | |
| US2890983A (en) | Excipient | |
| RU2129423C1 (en) | Ointment for treating burns and infected injuries |